The Center for Integrative Genomics (CIG) of the Faculty of Biology and Medicine at the University of Lausanne (UNIL) is seeking to host a new Swiss National Science Foundation (SNSF) Starting Grant Professor and encourages applications from outstanding researchers in the life sciences. Please consult eligibility criteria and find detailed application instructions at:
The CIG comprises 15 research groups. We actively promote careers of junior independent investigators, and current faculty include two Principal Investigators supported by early career programmes. The department is characterized by the diversity of research topics and approaches, but we are strongly grounded in the broad fields of genetics and genomics, from gene regulation to the molecular basis of complex traits. Our research employs a wide range of model systems and state-of-the-art experimental/analytical methods. More information about the CIG can be found here: https://www.unil.ch/cig.
We encourage prospective candidates to apply by October 31, 2023 by submitting a CV (including the names of three referees) and a short project description (up to three pages) as a single PDF file to Nicole.Vouilloz@unil.ch.
Interviews will be conducted in November 2023 at the CIG. The CIG faculty will decide shortly after which candidate(s) will be supported to apply for an SNSF Starting Grant Professorship (submission deadline expected to be in early 2024).
SNSF Starting Grant recipients will receive support from the CIG in the form of research space, state-of-the-art facilities, access to technical platforms in genomics, proteomics and imaging, necessary animal housing, logistics and administrative support, as well as the possibility of an additional year’s salary beyond the five-year funding period of the grant.
UNIL is an equal opportunity and family-friendly employer committed to excellence through diversity.
The Groningen Institute for Evolutionary Life Sciences is looking for an Assistant Professor, who can strengthen their position in the field of Behavioural Neuroscience, with an emphasis on neurobiological studies of behaviour under ecologically relevant conditions. The new staff member is expected to set up an independent research line within this field, complementary to the current neurobiological, evolutionary and ecological research in the GELIFES. The successful candidate is expected to take an integrative approach to address their research questions, and develop a strong research programme in Behavioural Neuroscience, focusing on the neurobiological mechanisms underlying complex behaviour in non-domesticated animal species under semi-natural conditions. With this profile the candidate is expected to develop a group that can successfully apply for competitive funding from e.g. topical programs of the Dutch Science Council and European funding schemes (e.g., related to neuropsychiatric disorders).
We offer you a full-time position and excellent career opportunities in our faculty’s career system Career Paths in Science and Engineering, including the perspective to get a permanent appointment (tenure) in 1-3 years and become Full Professor in approximately 10 years.
Consider our website for more information about the working conditions at the University of Groningen: https://www.rug.nl/about-ug/work-with-us/
The Research and Innovation Department of the Faculty of Biology and Medicine of the University of Lausanne is thrilled to invite you to the second edition of the event “Technology platforms: cutting-edge infrastructures to support research“. The event will take place on December 4th2023 from 13:00 to 19:00 on the campus in the Agora building.
This event is aimed at both fundamental and clinical researchers. It’s a unique opportunity to explore state-of-the-art research infrastructures and engage in conversation with the platform directors.
Stay tuned for the detailed program, which will be announced soon here!
The event is free of charge, but registration is mandatory. Please secure your spot by registering via the following link by November 28th: /register/239
An apéro will follow the event.
two-year post-doctoral position: Preclinical R&D of molecular imaging and theranostic agents for dysangiogenic diseases.
- Application Deadline: October 8th (Late applications may be considered if the position remains unfilled.)
- Activity Leader: Professor Philippe Garrigue.
Affiliation: PU-PH Radiopharmacy, University Hospitals of Marseille, Department of Medicines and Health Safety, Faculty of Pharmacy, Aix-Marseille University.
Research Centers: Center for Cardiovascular and Nutrition Research (C2VN, UMR AMU INSERM 1263 INRAE 1260), European Center for Medical Imaging Research (CERIMED, UAR AMU CNRS 2012
Biomed Pharmacother. 2023 Sep 30:167:115623.
doi: 10.1016/j.biopha.2023.115623. Online ahead of print.
Meijian Zhang 1, Emma Barroso 1, Maria Ruart 1, Lucía Peña 1, Mona Peyman 1, David Aguilar-Recarte 1, Marta Montori-Grau 1, Patricia Rada 2, Clara Cugat 1, Carla Montironi 3, Mohammad Zarei 4, Javier Jurado-Aguilar 1, Antoni Camins 5, Jesús Balsinde 6, Ángela M Valverde 2, Walter Wahli 7, Xavier Palomer 1, Manuel Vázquez-Carrera 8
Elafibranor is a dual peroxisome proliferator-activated receptor (PPAR)α and β/δ agonist that has reached a phase III clinical trial for the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD). Here, we examined the effects of elafibranor in mice fed a choline-deficient high-fat diet (CD-HFD), a model of metabolic dysfunction-associated steatohepatitis (MASH) that presents obesity and insulin resistance. Our findings revealed that elafibranor treatment ameliorated steatosis, inflammation, and fibrogenesis in the livers of CD-HFD-fed mice. Unexpectedly, elafibranor also increased the levels of the epithelial-mesenchymal transition (EMT)-promoting protein S100A4 via PPARβ/δ activation. The increase in S100A4 protein levels caused by elafibranor was accompanied by changes in the levels of markers associated with the EMT program. The S100A4 induction caused by elafibranor was confirmed in the BRL-3A rat liver cells and a mouse primary hepatocyte culture. Furthermore, elafibranor reduced the levels of ASB2, a protein that promotes S100A4 degradation, while ASB2 overexpression prevented the stimulating effect of elafibranor on S100A4. Collectively, these findings reveal an unexpected hepatic effect of elafibranor on increasing S100A4 and promoting the EMT program.